New diabetes drug Empagliflozin significantly reduces cases of heart failure in both diabetics and non-diabetics

Prashasti Awasthi Mumbai | Updated on November 17, 2020

This drug did not seem to trigger hypoglycemia, or low blood sugar, in non-diabetic patients

A recently developed drug for diabetes patients — Empagliflozin — can help in the treatment of heart failure in both diabetics and non-diabetics.

The findings of the clinical trial were published in the Journal of the American College of Cardiology. It revealed that this medication can improve the heart’s size, shape, and function. It also leads to better exercise capacity and quality of life. This may further reduce hospitalisations for heart failure patients

Also read: Massive surge in diabetes queries amid Covid-19: Practo

Author Carlos Santos-Gallego from Mount Sinai Hospital in the US: “Our clinical trial’s promising results show this diabetes drug can ameliorate lives of heart failure patients with reduced ejection fraction, enhance their exercise capacity, and improve their quality of life with little to no side effects.”

“Our study also identifies why this drug is effective: because it improves heart function, something that has not been understood until now,” Santos-Gallego added.

Also read: Polypill saves lives, cuts heart-related incidents by up to 40%: Study

Notably, the researchers mentioned that this drug did not seem to trigger hypoglycemia, or low blood sugar, in non-diabetic patients.


For the trial, researchers enrolled 84 patients with chronic heart failure with reduced ejection fraction (EF) — the percentage of blood the left ventricle pumps with each contraction

Published on November 17, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor